摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氨基苯丙酮 | 1197-05-3

中文名称
3-氨基苯丙酮
中文别名
——
英文名称
1-(3-amino-phenyl)-propan-1-one
英文别名
3’-aminopropiophenone;1-(3'-amino-phenyl)-propanone;3-aminopropiophenone;1-(3-Amino-phenyl)-propan-1-on;3-Amino-propiophenon;3'-Aminopropiophenone;1-(3-aminophenyl)propan-1-one
3-氨基苯丙酮化学式
CAS
1197-05-3
化学式
C9H11NO
mdl
MFCD00831416
分子量
149.192
InChiKey
CGXJUBDTCAAXAY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    0°C
  • 沸点:
    0°C
  • 密度:
    1.067±0.06 g/cm3(Predicted)
  • 闪点:
    0°C

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.222
  • 拓扑面积:
    43.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险类别码:
    R36/37/38,R
  • 海关编码:
    2922399090
  • 安全说明:
    S26,S36
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:3a4a3032cb7d1b9669a56bf5eb6f208a
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-氨基苯丙酮 在 copper(I) chloride 、 盐酸 、 sodium nitrite 作用下, 生成 3'-氯丙酮苯
    参考文献:
    名称:
    The Mechanistic Fate of the Anilino Moiety in the Rearrangement of α-Anilinoketones
    摘要:
    DOI:
    10.1021/ja01058a028
  • 作为产物:
    描述:
    苯丙酮盐酸tin硝酸 作用下, 生成 3-氨基苯丙酮
    参考文献:
    名称:
    Comanducci; Pescitelli, Gazzetta Chimica Italiana, 1906, vol. 36 II, p. 785
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES<br/>[FR] DERIVES DE 2,3,6-TRISUBSTITUE 4-PYRIMIDONE
    申请人:MITSUBISHI PHARMA CORP
    公开号:WO2004085408A1
    公开(公告)日:2004-10-07
    A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C1-C12 alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C1-C8 alkyl group, an optionally partially hydrogenated C6-C10 aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each Y independently represents a halogen atom, a hydroxy group, a cyano group, a C1-C6 alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C2-C6 alkylene group.
    一种具有tau蛋白激酶1抑制活性的嘧啶酮衍生物,其由化学式(I)或其盐、溶剂合物或水合物表示;用于预防和/或治疗神经退行性疾病(例如阿尔茨海默病);其中Q代表CH或氮原子;R代表C1-C12烷基基团;化学式(I)的环:代表哌嗪环或哌啶环;每个X独立地代表C1-C8烷基基团、可选择性部分氢化的C6-C10芳环、茚环或类似物;m代表1到3的整数;每个Y独立地代表卤素原子、羟基、氰基、C1-C6烷基基团或类似物;n代表0到8的整数;当X和Y或两个Y基团连接在同一碳原子上时,它们可以结合形成C2-C6烷基基团。
  • [EN] SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS<br/>[FR] COMPOSÉS DE TRIAZOLE ET D'IMIDAZOLE SUBSTITUÉS
    申请人:HOFFMANN LA ROCHE
    公开号:WO2014086663A1
    公开(公告)日:2014-06-12
    The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.
    这项发明涉及式(I)的化合物及其药用可接受的盐。此外,本发明涉及制造和使用式(I)的化合物的方法,以及含有这种化合物的药物组合物。式(I)的化合物是LMP7抑制剂,可能在治疗相关的炎症性疾病和紊乱方面有用,例如类风湿性关节炎、红斑狼疮和肠易激综合征。
  • [EN] PRODUCTION OF N-ALKYLAMIDE COMPOUNDS<br/>[FR] PRODUCTION DE COMPOSES DE N-ALKYLAMIDE
    申请人:TAKASAGO PERFUMERY CO LTD
    公开号:WO2004087637A1
    公开(公告)日:2004-10-14
    The present invention provides an efficient process for the production of N-acylaniline derivatives by selectively alkylating an amide group at the nitrogen atom. The process comprises reacting an amide compound of the formula (2): (wherein, R1 and R2 are each independently an alkyl group, a substituted alkyl group, an alkenyl group, a substituted alkenyl group, an aryl group or a substituted aryl group) with a sulfuric acid ester in the presence of a solid metal hydroxide to give an N-alkylamide compound of the formula (3): (wherein R3 is an alkyl group and R1 and R2 have each the same meaning as described above).
    本发明提供了一种通过选择性地烷基化氮原子上的酰胺基团来生产N-酰苯胺衍生物的高效过程。该过程包括在固体金属羟基的存在下,将式(2)的酰胺化合物(其中,R1和R2分别独立地是烷基、取代烷基、烯基、取代烯基、芳基或取代芳基)与硫酸酯反应,得到式(3)的N-烷基酰胺化合物(其中R3是烷基,R1和R2的含义与上述相同)。
  • Palladium-Catalyzed Coupling of Ammonia with Aryl Chlorides, Bromides, Iodides, and Sulfonates: A General Method for the Preparation of Primary Arylamines
    作者:Giang D. Vo、John F. Hartwig
    DOI:10.1021/ja903049z
    日期:2009.8.12
    for the coupling of ammonia with aryl chlorides, bromides, iodides, and sulfonates. The couplings of ammonia with this catalyst conducted with a solution of ammonia in dioxane form primary arylamines from a variety of aryl electrophiles in high yields. Catalyst loadings as low as 0.1 mol % were sufficient for reactions of many aryl chlorides and bromides. In the presence of this catalyst, aryl sulfonates
    我们报告说,由 Pd[P(o-tol)(3)](2) 和烷基双膦 CyPF-t-Bu 生成的复合物是一种高活性和选择性的催化剂,用于将氨与芳基氯化物、溴化物、碘化物、和磺酸盐。用氨在二恶烷中的溶液进行的氨与该催化剂的偶联以高产率从各种芳基亲电试剂形成伯芳基胺。低至 0.1 mol% 的催化剂负载量足以进行许多芳基氯化物和溴化物的反应。在这种催化剂的存在下,芳基磺酸盐也首次以高产率与氨偶联。将这种催化剂存在下的反应与现有铜和钯系统存在下的反应进行比较,揭示了互补的底物范围,如果不是更广泛的话。该方法用于生成酰胺、酰亚胺、和氨基甲酸酯通过从芳基溴化物和氯化物、氨和酰基氯或酸酐一锅合成这些羰基化合物的小库来说明。机理研究表明,与使用 CyPF-t-Bu 和钯 (II) 作为催化剂前体,因为钯 (II)、氨和碱的组合产生的活性催化剂浓度低。
  • Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use
    申请人:Agouron Pharmaceuticals, Inc.
    公开号:US20020025976A1
    公开(公告)日:2002-02-28
    Diaminothiazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    二氨基噻唑化合物可调节和/或抑制特定蛋白激酶的活性。这些化合物及含有它们的药物组合物能够介导酪氨酸激酶信号传导,以调节和/或抑制不需要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途,以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态,如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
查看更多